Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3359 |
| PDBID: | 7A6O |
| Chains: | B_A |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 2.12 |
| Reference: | 10.1038/s41467-021-22634-x |
| Antibody | |
| Antibody: | VHH81 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | Caplacizumab(Approved) |
| Antigen | |
| Antigen: | Recombinant von Willebrand factor AIM-A1 domain |
| Antigen mutation: | No |
| Durg Target: | P04275 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >7A6O_B|Chain B|VHH81 Nanobody fragment|Lama glama (9844) EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS |
Antigen
Chain: A
Mutation: NULL
| >7A6O_A|Chain A|von Willebrand factor|Homo sapiens (9606) ISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRIALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition B: ARG28 THR29 PHE30 SER31 TYR32 SER53 ARG54 THR55 SER58 ASN75 ALA76 ARG78 GLY101 ALA104 GLU105 ASP106 GLY107 ARG108 A: ILE1262 SER1263 GLU1264 PRO1265 PRO1266 LEU1267 HIS1268 ASP1269 PHE1270 TYR1271 CYS1272 SER1273 ARG1274 ARG1308 TRP1313 CYS1458 ASP1459 GLU1463 ALA1464 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
